Stevanato Group (NYSE:STVN) Insider Sells €293,453.50 in Stock

Stevanato Group S.p.A. (NYSE:STVN) insider Mauro Stocchi sold 13,649 shares of the stock in a transaction dated Monday, September 28th. The shares were sold at an average price of €21.50, for a total transaction of €293,453.50. Following the transaction, the insider directly owned 400,000 shares of the company’s stock, valued at €8,600,000. This trade represents a 3.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Stevanato Group Price Performance

Shares of STVN stock traded down €0.24 during trading hours on Wednesday, hitting €20.96. The stock had a trading volume of 192,808 shares, compared to its average volume of 510,750. Stevanato Group S.p.A. has a one year low of €12.89 and a one year high of €27.99. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. The stock’s 50-day moving average price is €21.06 and its two-hundred day moving average price is €18.37. The stock has a market capitalization of $6.35 billion, a price-to-earnings ratio of 37.42, a PEG ratio of 1.75 and a beta of 0.75.

Stevanato Group (NYSE:STVN) last posted its earnings results on Wednesday, August 5th. The company reported €0.14 EPS for the quarter, missing analysts’ consensus estimates of €0.15 by (€0.01). Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%.The firm had revenue of €302.00 million during the quarter. Equities analysts forecast that Stevanato Group S.p.A. will post 0.69 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. TD Cowen upgraded Stevanato Group to a “strong-buy” rating in a research report on Wednesday, June 17th. Weiss Ratings upgraded shares of Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Wolfe Research started coverage on shares of Stevanato Group in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $21.00 price objective for the company. Finally, UBS Group assumed coverage on shares of Stevanato Group in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $23.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Stevanato Group has a consensus rating of “Moderate Buy”.

Institutional Investors Weigh In On Stevanato Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STVN. Integrated Wealth Concepts LLC bought a new stake in shares of Stevanato Group in the 2nd quarter valued at approximately $59,000. Squarepoint Ops LLC increased its position in shares of Stevanato Group by 131.2% during the 2nd quarter. Squarepoint Ops LLC now owns 193,311 shares of the company’s stock valued at $3,493,000 after purchasing an additional 109,702 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of Stevanato Group during the 2nd quarter valued at approximately $22,621,000. Ranger Investment Management L.P. purchased a new stake in Stevanato Group during the 2nd quarter valued at $21,438,000. Finally, Handelsbanken Fonder AB raised its holdings in Stevanato Group by 26.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 30,600 shares of the company’s stock valued at $553,000 after buying an additional 6,400 shares during the period.

Stevanato Group Company Profile

Stevanato Group S.p.A. is an Italy-based provider of drug-containment, drug-delivery and diagnostic solutions for the pharmaceutical, biotechnology and healthcare industries. The company serves customers across the development, production and administration of injectable medicines, with activities spanning pharmaceutical glass packaging, medical devices and manufacturing technologies.

Its product portfolio includes glass vials, cartridges, syringes and other primary containers, as well as ready-to-use packaging solutions such as EZ-fill.